Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Geneva: The World Health Organization (WHO) has issued a global safety alert highlighting the risk of non-arteritic anterior ...

The most read stories this past month detailed the passing of Dimitrios Karmpaliotis and news on Evoque and COVID-19.

NAION risk is most significant within the first 12 months of beginning semaglutide, and is highest in patients with additional risk factors.

Driven by a desire to help ex-servicemembers with post-traumatic stress disorder and other mental illnesses, GOP lawmakers ...

WHO issues alert on the use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy: Geneva Saturday, June 28, 2025, 11:00 Hrs [IST] WHO is alerting ...

As a mass rollout of weight loss injections begins across the NHS, with GPs able to prescribe Mounjaro for the first time ...

Many of us are dying to be skinny. We will do most anything it takes to get there, even risk our health. So, when Wegovy and ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...